 |
18 Diseases |  |
32 Trials |
|
32 Trials |  |
839 News |  |
| «12...45678910111213141516 |
- ||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
New P2 trial: The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX (clinicaltrials.gov) - Jan 18, 2012
P2, N=692, Completed, Sponsor: Merck Sharp & Dohme Corp.
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Humira (adalimumab) / AbbVie
New P4 trial, Pneumococcal vaccines: Efficacy Study of Pneumococcal Vaccination in Crohn's Disease (clinicaltrials.gov) - Jan 5, 2012
P4, N=172, Recruiting, Sponsor: Kyunghee University Medical Center
- Isentress (raltegravir) / Merck (MSD)
Trial termination: RAG-1/2: Immune Responses in Patients Treated With Raltegravir (clinicaltrials.gov) - Sep 26, 2011
P3, N=0, Terminated, Sponsor: McGill University Health Center
Active, not recruiting --> Terminated; Unexpected and severe difficulties in recruitment.
- Isentress (raltegravir) / Merck (MSD)
Enrollment change: RAG-1/2: Immune Responses in Patients Treated With Raltegravir (clinicaltrials.gov) - Sep 26, 2011
P3, N=0, Terminated, Sponsor: McGill University Health Center
Active, not recruiting --> Terminated; Unexpected and severe difficulties in recruitment. N=60 --> 0
- lenalidomide / Generic mfg.
Enrollment open: Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Sep 19, 2011
P2, N=48, Recruiting, Sponsor: National Cancer Institute (NCI)
N=60 --> 0 Not yet recruiting --> Recruiting
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P3 trial, Pneumococcal vaccines: Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines (clinicaltrials.gov) - Sep 8, 2011
P3, N=4, Active, not recruiting, Sponsor: University of Oxford
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
New P2 trial: PCVFU: Pneumococcal Conjugate Vaccine Followup (clinicaltrials.gov) - Aug 9, 2011
P2, N=280, Completed, Sponsor: William Pomat